Skip to main content

Billionaire Tom Steyer ends 2020 presidential bid

Billionaire Tom Steyer ended his campaign for the Democratic presidential nomination after a disappointing finish in South Carolina, where he had hoped to make a stand.

Steyer didn’t garner enough of the vote to get any delegates. He had been betting on a strong performance in that state after doing poorly in the first three early contests, failing to crack the top four slots in Iowa, New Hampshire and Nevada.

“I can’t see a path where I can win the presidency,” Steyer said in Columbia, South Carolina. “I have no regrets.”

In South Carolina, he spent millions on television ads before the other candidates invested in the state.

Steyer entered the race in July on a platform of reforming the role of money in politics and combating climate change. He also brought a willingness to spend freely from his personal fortune to deliver his message.

His departure leaves Michael Bloomberg as the only candidate left in the race who is self-funding his campaign.

(Bloomberg is the founder and majority owner of Bloomberg LP, the parent company of Bloomberg News.)

Steyer decided to run despite announcing in January 2019 that he wouldn’t seek the presidency and would instead focus on Need to Impeach, his advocacy organization devoted to removing President Donald Trump from office.

Steyer vowed to spend $100 million on his campaign. He spent almost three times that much, with expenditures of $271 million through the end of January.

He participated in four debates. Despite his efforts, Steyer never rose to be a top-tier candidate. He averaged at or below 2% nationally throughout the race according to RealClearPolitics.

Before running for president, Steyer founded Farallon Capital where he served as a co-senior managing partner and was a partner and member of the executive committee of private equity firm Hellman & Friedman. He and his wife signed the “giving pledge” agreeing to donate half of their net worth to charity within their lifetime. In 2013, Steyer launched the progressive political action committee NextGen America, which works to mobilize young voters and push progressive issues.

More must-read stories from Fortune:

—Are we undergoing an industrial revolution or a phase change?
—Twitter’s testing new ways to fight misinformation. Is open-source the answer?
—Meet Trump’s Giuliani-approved power broker—and Melania’s new senior adviser
—Angela Merkel is on her way out. Meet her potential replacements
—How the 2020 election could influence your personal finances

Get up to speed on your morning commute with Fortune’s CEO Daily newsletter.



from Fortune https://ift.tt/3ckChVO
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more